DNA methylation is a heritable epigenetic marker which involves the covalent transfer of a methyl group to the C-5 position of the cytosine ring of DNA by enzymes known as DNA methyltransferases (DNMTs). In humans, DNA methylation occurs primarily at cytosines in any context of the genome. More than 98% of DNA methylation occurs in a CpG dinucleotide context in somatic cells. The current study aims to assess the global DNA methylation market by focusing on evaluating products catering to the aforementioned definition. The current scenario of DNA methylation detection and diagnosis is mainly dominated by several diagnostic majors, such as Illumina, Inc., Thermo Fisher Scientific Inc., Merck Group, and QIAGEN N.V., which offer a wide variety of products ranging from molecular-genetic tests to sequencing instruments for the confirmatory detection and diagnosis of DNA methylation. These products are generally based on technologies, such as polymerase chain reaction (PCR), microarrays, and sequencing, including both traditional and next-generation sequencing. The underlying utility of diagnostic testing for DNA methylation is based on the identification of clinically actionable genetic function, which provide crucial information on diagnosis, prognosis, and theranostics of genetic disorders and thereby facilitates clinical work-up, treatment management, and therapeutic selection.

1. Product Definition 

2. Market Scope 

3. Research Methodology 

4. Market Overview 

5. Global DNA Methylation Market: Industry Analysis

6. Global DNA Methylation Market: Market Dynamics

7. Competitive Landscape

8. Global DNA Methylation Market (by Product Type)

9. Global DNA Methylation Market (by Technology) 

10. Global DNA Methylation Market (by Application) 

11. Global DNA Methylation Market (by End User)

12. Global DNA Methylation Market (by Region) 

13. Company Profiles